The reference is made to the stock exchange notice dated April 25, 2012 regarding the approval of NorDiag's Annual financial statements for 2011. Please find attached the complete Annual Report for 2011. The Annual Report is also available on www.nordiag.com.
 
For further information, please contact:
CEO Mårten Wigstøl, Phone: +47 911 65775
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 

ANNUAL REPORT 2011

Read the notice in Norwegian here.